Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04972604 · ClinicalTrials.gov registry record
CureDuchenne Link®: A Resource for Research
A clinical trial of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy, sponsored by CureDuchenne.
- Recruiting
- Registry status
- 5,000
- Enrollment target
- 10
- Study locations
NCT04972604: Recruiting study of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy, sponsored by CureDuchenne.
NCT04972604 is a study of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy that is actively recruiting participants, run by CureDuchenne. The registered enrollment target is 5,000 participants, above the 308-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (1523% higher). The trial reports 10 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04972604, a study of Duchenne Muscular Dystrophy and Becker Muscular Dystrophy, is actively recruiting participants, sponsored by CureDuchenne.
- RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 10
- Study locations
Study Summary
CureDuchenne link is a data hub comprised of integrated biospecimens, clinical data, and self- and/or caregiver-reported information from participants. Anyone over 4 weeks old who has been diagnosed with DMD or BMD or who is a carrier of DMD or BMD can join. Parents or legal guardians can sign up their child(ren).
Primary Outcome
There is no intervention in this project. Participants will provide documentation to support their diagnosis of Duchenne muscular dystrophy, Becker muscular dystrophy, or a carrier of these mutations
Conditions Studied
Study Locations (10)
California
- CureDuchenne - Newport Beach
- Children's Hospital of Orange County - Orange
Arkansas
- Arkansas Children's Hospital - Little Rock
Georgia
- Rare Disease Research - Atlanta
Iowa
- University of Iowa - Iowa City
Kansas
- Kansas University Clinical Research Center - Fairway
Michigan
- Corewell Health - Grand Rapids
North Carolina
- Rare Disease Research Center - Hillsborough
Pennsylvania
- Penn State Health - Hershey
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2021-07-09 |
| Est. Completion | 2031-07-09 |
What NCT04972604 shows while recruiting
NCT04972604 is an observational study that tracks outcomes without assigning an intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 308-participant average among 48 other Duchenne Muscular Dystrophy trials with a reported enrollment target (1523% higher).
The record links to 2 conditions, with Duchenne Muscular Dystrophy appearing as the primary indexed condition, and to 0 interventions.
NCT04972604 lists 10 locations in 9 states (California, Arkansas, Georgia).
Frequently Asked Questions
What is clinical trial NCT04972604 about?
NCT04972604 is a clinical study titled "CureDuchenne Link®: A Resource for Research". CureDuchenne link is a data hub comprised of integrated biospecimens, clinical data, and self- and/or caregiver-reported information from participants. Anyone over 4 weeks old who has been diagnosed with DMD or BMD or who is a carrier of DMD or BMD can join. Parents or legal guardians can sign up th...
What is the current status of trial NCT04972604?
This trial is currently recruiting. The enrollment target is 5,000 participants. The study started on 2021-07-09. Estimated completion is 2031-07-09.
What conditions does trial NCT04972604 study?
This clinical trial studies the following conditions: Duchenne Muscular Dystrophy, Becker Muscular Dystrophy.
Who is sponsoring clinical trial NCT04972604?
This trial is sponsored by CureDuchenne, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04972604 being conducted?
This trial has 10 study locations across Arkansas, California, Georgia, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Duchenne Muscular Dystrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04972604's enrollment target sits among peer trials
5,000 2nd of 48 the highest of 48 other Duchenne Muscular Dystrophy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Duchenne Muscular Dystrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
RECRUITING · Phase 1
-
AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Satralizumab in Duchenne Muscular Dystrophy (DMD)
RECRUITING · Phase 2
-
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
RECRUITING · Phase 2
-
Once Weekly Infant Corticosteroid Trial for DMD
RECRUITING · Phase 4
-
The Duchenne Registry
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00060541 · 5,000 participants
Evaluation and Treatment of Neurosurgical Disorders
- NCT00575081 · 5,000 participants
Physiological Brain Atlas Development
- NCT00736749 · 5,000 participants
Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies
- NCT00900198 · 5,000 participants
Collection of Tissue Samples for Cancer Research
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI